...
首页> 外文期刊>Histopathology: Official Journal of the British Division of the International Academy of Pathology >Virtual tissue microarrays: A novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situ
【24h】

Virtual tissue microarrays: A novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situ

机译:虚拟组织微阵列:一种新颖可行的优化组织微阵列用于生物标记物研究的原位导管癌的方法

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: Tissue microarrays (TMAs) are effective tools for performing high-throughput standardization analyses of biomarkers, but evidence indicating the core number required to be representative of the whole tumour is lacking. Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. The number and size of cores that can best represent a DCIS lesion are unknown. Rather than performing extensive experiments using several variants of physical TMAs, the aim of this study was to develop a 'virtual TMA' approach that is effective at optimizing biomarker discovery and validation. Methods and results: Whole DCIS sections from 95 patients were evaluated by immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki67. Histoscores were generated manually for ER, PgR, and HER2, as well as percentage positivity for Ki67. Slides were scanned using the FDA-approved Ariol SL50 Image Analysis system, and the virtual array (V-Array) module was used. Virtual cores created virtual TMAs, and our validated scoring classifiers were applied. Automated histoscores and percentage positivity were determined, and compared against increasing numbers of cores. The optimal number of cores was based on concordant results between virtual TMAs and corresponding whole sections. Conclusions: We have shown that virtual arrays constitute an important tool in digital pathology in both research and clinical settings.
机译:目的:组织微阵列(TMA)是进行生物标记物高通量标准化分析的有效工具,但缺乏表明代表整个肿瘤所需的核心数量的证据。导管原位癌(DCIS)是浸润性乳腺癌的非专性前体。最能代表DCIS病变的核的数量和大小尚不清楚。与其使用物理TMA的几种变体进行广泛的实验,本研究的目的是开发一种有效优化生物标记物发现和验证的“虚拟TMA”方法。方法和结果:对95例患者的DCIS整个切片进行了免疫组织化学评估,评估其雌激素受体(ER),孕激素受体(PgR),HER2和Ki67的水平。 ER,PgR和HER2的组织得分是人工生成的,Ki67的阳性率为百分比。使用FDA批准的Ariol SL50图像分析系统扫描载玻片,并使用虚拟阵列(V-Array)模块。虚拟核心创建了虚拟TMA,并应用了我们经过验证的评分分类器。确定了自动化的组织比分和阳性率,并与增加的核数进行了比较。最佳核数是基于虚拟TMA与相应的整个部分之间一致的结果。结论:我们已经表明,虚拟阵列是研究和临床环境中数字病理学的重要工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号